Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Phase 4TerminatedNCT01104311

Asan Medical Center132 enrolled

Overview

To develop adequate blood pressure (BP) lowering strategy after subacute ischemic stroke patients with symptomatic severe intracranial atherosclerosis. Primary hypothesis of this study is that aggressive BP control (lowering systolic BP between 110mmHg and 120mmHg) will not increase the ischemic lesion volumes in hemisphere compared to modest BP lowering (lowering systolic BP between 130mmHg and 140mmHg) in the patients with symptomatic severe intracranial atherosclerosis.

The benefits of BP lowering in the prevention of primary and secondary prevention of stroke is established well, although absolute target BP level is uncertain. Current guidelines defined the normal BP as \<120/80mmHg and recommend individualized target BP level. Large well performed stroke prevention trials consistently showed that reduction of 10/5mmHg in patients with systolic BP below 140mmHg had clear benefits in the prevention of cardiovascular events. However, we have a dilemma about BP control in the patients with severe intracranial atherosclerosis. Aggressive BP control will be more effective in the prevention of overall cardiovascular events than modest BP control, but aggressive BP control will reduce cerebral perfusion in the territory of severe intracranial disease and may increase the risk of ischemic damage. The study will try to reveal aggressive BP control in the patients with symptomatic severe intracranial atherosclerosis is not increase ischemic lesion volume in hemisphere to compare modest BP control.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

132

Conditions

Brain Ischemia

Interventions

Aggressive BP loweringPROCEDURE

adjust the amount and number of antihypertensive drugs to lowering of systolic blood pressure to target level

modest blood pressure loweringPROCEDURE

adjust the amount and number of antihypertensive drugs

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * acute symptomatic ischemic stroke having relevant lesion on DWI(Diffusion weighted image) MRI 7 days after and 42 days within onset. * relevant stenosis(more than 50%) or occlusion from MCA(middle cerebral artery)(M1) to distal of ICA(internal carotid artery ) on MR(Magnetic resonance) angiogram or CT angiogram. * mean systolic blood pressure\>=140mmHg or taking antihypertensive drug on screening. Exclusion Criteria: * taking more than 3 antihypertensive drugs and mean systolic blood pressure\>=150mmHg on screening. * history of recent thrombolysis but stenosis or occlusion remained after thrombolysis. * evidence of orthostatic hypotension * suspicious embolic cerebrovascular stenosis * planned state of cerebrovascular surgery or angioplasty or stent 7 months within screening. * severe stroke-NIHSS\>=16 * mean systolic blood pressure\>=200mmHg which is not able to control on screening. * abnormal blood test finding (abnormal LFT(liver function test), anemia, renal insufficiency) * pregnant or breast-feeding * severe stroke sequela or medical problem * suspicious secondary hypertension * disease causing edema or significant ankle edema on screening. * severe heart failure which correspond to NYHA (New York Heart Association )heart failure classification class III or IV. * inappropriate condition determined by investigator * Patient who do not have FLAIR image on or two months prior to screening.

Locations (16)

Chungnam National University Hospital

Daejeon, Chungcheongnam-do, South Korea

Myongji Hospital

Goyang-si, Gyeonggi-do, South Korea

Wonkwang University Hospital

Outcomes

Primary Outcomes

Ischemic Lesion Volume Change in the Whole Forebrain on Fluid Attenuation Inversion Recovery (FLAIR) Magnetic Resonance Imaging (MRI)

The difference between final ischemic lesions volume and base ischemic lesions of both hemisphere on FLAIR MRI

Time frame: Screening to 24 weeks

Secondary Outcomes

Change of the Ischemic Lesion Volume in Cerebral Hemisphere on FLAIR From Screening to Week 24 in FAS Population

the difference between final ischemic lesions volume and base ischemic lesions in the territory of symptomatic intracranial disease on FLAIR MRI

Time frame: 24 weeks

The Number of Patients With New Ischemic Lesion in the Whole Forebrain on FLAIR MRI

Time frame: 24 weeks

Number of Participants With Cardiovascular Events From Screening to Week 24 in ITT Population.

Time frame: 24 weeks

Total Number of Cardiovascular Events Form Screening to Week 24 in ITT Population.

Time frame: 24 Week

Number of Participants With Vascular Death From Screening to Week 24 in ITT Population.

Time frame: 24 Weeks

Number of Participants With Adverse Events

Number of Participants with Adverse Events

Time frame: 24 Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.